Research programme: cancer therapeutics - Hutchison MediPharma
Latest Information Update: 25 Sep 2015
At a glance
- Originator Hutchison MediPharma
- Class Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours